Bringing Relief to Patients with Neuropathic Pain
Developing repurposed drugs to restore the quality of life of patients suffering from chronic, debilitating neuropathic pain conditions
Who we are
Undaunted Bio is a seed-stage startup using a clinically informed, AI-driven, network-medicine approach to repurposing existing drugs for neuropathic pain
Our Pipeline
Our current pipeline is focused on UDB412, a promising lead candidate for the treatment of the severe pain of Trigeminal Neuralgia, a debilitating facial pain condition with a significant unmet medical need. We intend to broaden the indication of UDB412 to other neuropathic pain conditions, such as diabetic neuropathic pain.
Our Approach
We have clinical evidence, from off-label, compassionate use of the clinical effectiveness of UDB412 in Trigeminal Neuralgia. We aim to develop an Oral Thin Film reformulation of UDB412 via the FDA’s 505(b)(2) pathway.
Help us bring relief to patients with trigeminal neuralgia and other life-altering neuropathic pain conditions